Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	2359	95635-55-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ranolazine hydrochloride ranolazine ranexa renexa ranolazine HCl	An acetanilide and piperazine derivative that functions as a SODIUM CHANNEL BLOCKER and prevents the release of enzymes during MYOCARDIAL ISCHEMIA. It is used in the treatment of ANGINA PECTORIS. Molecular weight: 427.55 Formula: C24H33N3O4 CLOGP: 1.01 LIPINSKI: 0 HAC: 7 HDO: 2 TPSA: 74.27 ALOGS: -3.59 ROTB: 9 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ranolazine hydrochloride
ranolazine
ranexa
renexa
ranolazine HCl

An acetanilide and piperazine derivative that functions as a SODIUM CHANNEL BLOCKER and prevents the release of enzymes during MYOCARDIAL ISCHEMIA. It is used in the treatment of ANGINA PECTORIS.

Molecular weight: 427.55
Formula: C24H33N3O4
CLOGP: 1.01
LIPINSKI: 0
HAC: 7
HDO: 2
TPSA: 74.27
ALOGS: -3.59
ROTB: 9

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1.50	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	6 %	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	42.50 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.20 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	9.50 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.38 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.80 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,MAP3K21,MAP3K7,MAPK7,MAPKAPK2,MET,MTOR,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,TEK,TGFBR1	37
kinase-selectivity-class	AXL,BRAF,DDR1,ERBB2,GRK2,MAPK7,PDK4,PIK3CD,SIK2	9
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
rat-kpuu-brain	Rat brain Kpuu	0.058	%	High	1

Approvals:

Date	Agency	Company	Orphan
Jan. 27, 2006	FDA	GILEAD

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bradycardia	120.83	18.52	80	7633	83767	90536967
Electrocardiogram QT prolonged	118.85	18.52	75	7638	72381	90548353
Drug interaction	74.52	18.52	104	7609	276349	90344385
Tonic clonic movements	68.76	18.52	18	7695	1704	90619030
Dizziness	64.04	18.52	149	7564	589135	90031599
Chest pain	61.71	18.52	103	7610	319542	90301192
Angina pectoris	55.47	18.52	37	7676	39123	90581611
Cardiac arrest	54.05	18.52	55	7658	104880	90515854
Pulseless electrical activity	49.48	18.52	21	7692	8911	90611823
Hyperkalaemia	48.78	18.52	42	7671	64922	90555812
Hypotension	40.51	18.52	87	7626	325310	90295424
Sinus bradycardia	39.41	18.52	22	7691	16930	90603804
Torsade de pointes	38.87	18.52	21	7692	15161	90605573
Syncope	38.82	18.52	52	7661	132611	90488123
Coronary artery disease	38.77	18.52	28	7685	33595	90587139
Stent placement	37.71	18.52	14	7699	4189	90616545
Serum serotonin increased	34.43	18.52	7	7706	215	90620519
Seizure	31.84	18.52	51	7662	152578	90468156
Chromaturia	31.76	18.52	20	7693	19167	90601567
Urinary straining	30.88	18.52	5	7708	40	90620694
Circumoral swelling	30.25	18.52	5	7708	46	90620688
Circulatory collapse	29.30	18.52	21	7692	24883	90595851
Catheterisation cardiac	28.61	18.52	12	7701	4944	90615790
Death	27.21	18.52	93	7620	456458	90164276
Product residue present	26.83	18.52	11	7702	4280	90616454
Pulmonary oedema	25.70	18.52	29	7684	62051	90558683
Hyponatraemia	25.65	18.52	43	7670	133495	90487239
Infusion related reaction	25.13	18.52	3	7710	416777	90203957
Ageusia	24.73	18.52	16	7697	16060	90604674
Myocardial infarction	24.30	18.52	37	7676	105935	90514799
Hypersensitivity pneumonitis	24.27	18.52	10	7703	3938	90616796
Dyspnoea	23.96	18.52	142	7571	880813	89739921
Wrong technique in product usage process	23.96	18.52	30	7683	71541	90549193
BRASH syndrome	23.46	18.52	8	7705	1871	90618863
Joint swelling	23.24	18.52	7	7706	503293	90117441
Hypoglycaemia	22.94	18.52	29	7684	69819	90550915
Fall	22.71	18.52	91	7622	481719	90139015
Therapeutic response unexpected	22.47	18.52	17	7696	21863	90598871
Sinus arrest	22.42	18.52	8	7705	2138	90618596
Myopathy	22.15	18.52	14	7699	13504	90607230
Autonomic nervous system imbalance	22.10	18.52	9	7704	3441	90617293
Intentional overdose	21.85	18.52	33	7680	93801	90526933
Coronary artery bypass	21.72	18.52	8	7705	2341	90618393
Gastrointestinal haemorrhage	21.38	18.52	32	7681	90216	90530518
Somnolence	20.57	18.52	51	7662	209033	90411701
Left ventricular hypertrophy	20.04	18.52	10	7703	6134	90614600
Nodal rhythm	19.84	18.52	7	7706	1811	90618923
Faeces pale	19.32	18.52	7	7706	1956	90618778
Labelled drug-drug interaction medication error	18.79	18.52	13	7700	14569	90606165
Rheumatoid arthritis	18.74	18.52	4	7709	362610	90258124

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dizziness	183.85	17.46	264	10265	248990	42361816
Chest pain	161.41	17.46	185	10344	139345	42471461
Syncope	82.88	17.46	112	10417	99294	42511512
Angina pectoris	78.43	17.46	65	10464	32831	42577975
Drug interaction	71.40	17.46	184	10345	266815	42343991
Stent placement	61.87	17.46	29	10500	5331	42605475
Coronary artery disease	59.83	17.46	70	10459	53650	42557156
Hypotension	58.26	17.46	167	10362	257464	42353342
Dyspnoea	54.90	17.46	235	10294	442386	42168420
Bradycardia	43.88	17.46	77	10452	85407	42525399
Death	36.32	17.46	219	10310	470966	42139840
Rhabdomyolysis	32.18	17.46	64	10465	77955	42532851
Chromaturia	28.87	17.46	27	10502	15962	42594844
Myocardial infarction	28.51	17.46	81	10448	123928	42486878
Heart valve stenosis	28.39	17.46	6	10523	73	42610733
Electrocardiogram QT prolonged	28.31	17.46	46	10483	47899	42562907
Cardiac failure congestive	28.11	17.46	64	10465	85538	42525268
Parkinsonian rest tremor	24.23	17.46	7	10522	324	42610482
Therapeutic response unexpected	24.05	17.46	21	10508	11360	42599446
Loss of consciousness	23.88	17.46	63	10466	92291	42518515
Product residue present	22.78	17.46	12	10517	2829	42607977
Myopathy toxic	22.41	17.46	8	10521	733	42610073
Angina unstable	21.97	17.46	20	10509	11428	42599378
Keratolysis exfoliativa acquired	21.92	17.46	3	10526	0	42610806
Aortic bruit	21.76	17.46	6	10523	234	42610572
Myocardial necrosis	20.76	17.46	6	10523	278	42610528
Respiratory tract haemorrhage	20.63	17.46	9	10520	1400	42609406
Vertigo	20.34	17.46	33	10496	34314	42576492
Catheterisation cardiac	20.15	17.46	11	10518	2783	42608023
Cardiac failure	20.04	17.46	65	10464	106791	42504015
Presyncope	19.79	17.46	26	10503	22361	42588445
Brugada syndrome	19.67	17.46	8	10521	1045	42609761
Coronary artery bypass	19.30	17.46	13	10516	4797	42606009
Completed suicide	19.30	17.46	60	10469	96405	42514401
Ventricular tachycardia	19.26	17.46	30	10499	30130	42580676
Coronary arterial stent insertion	19.00	17.46	12	10517	3973	42606833
Asthenia	18.13	17.46	125	10404	280668	42330138
Haematemesis	17.86	17.46	29	10500	30170	42580636

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Chest pain	185.67	16.96	247	15462	376128	110197462
Dizziness	174.97	16.96	336	15373	697857	109875733
Drug interaction	145.58	16.96	257	15452	499926	110073664
Bradycardia	144.76	16.96	142	15567	155375	110418215
Electrocardiogram QT prolonged	135.47	16.96	117	15592	108843	110464747
Syncope	125.28	16.96	149	15560	202387	110371203
Angina pectoris	123.19	16.96	88	15621	62207	110511383
Stent placement	103.89	16.96	39	15670	7195	110566395
Coronary artery disease	97.31	16.96	81	15628	71609	110501981
Hypotension	95.77	16.96	222	15487	523627	110049963
Death	82.78	16.96	252	15457	698617	109874973
Dyspnoea	62.62	16.96	316	15393	1106556	109467034
Myocardial infarction	57.34	16.96	100	15609	191983	110381607
Cardiac arrest	56.88	16.96	101	15608	196652	110376938
Rhabdomyolysis	56.07	16.96	77	15632	120324	110453266
Tonic clonic movements	53.89	16.96	19	15690	2933	110570657
Gastrointestinal haemorrhage	51.79	16.96	88	15621	165430	110408160
Chromaturia	45.80	16.96	36	15673	29324	110544266
Cardiac failure congestive	44.25	16.96	78	15631	150922	110422668
Angina unstable	43.92	16.96	28	15681	16404	110557186
Sinus bradycardia	43.53	16.96	35	15674	29448	110544142
Pulseless electrical activity	40.97	16.96	27	15682	16730	110556860
Coronary artery bypass	40.72	16.96	19	15690	6023	110567567
Catheterisation cardiac	40.28	16.96	19	15690	6172	110567418
Infusion related reaction	39.80	16.96	4	15705	381158	110192432
Hypoglycaemia	39.35	16.96	64	15645	116040	110457550
Acute myocardial infarction	38.12	16.96	53	15656	83724	110489866
Coronary arterial stent insertion	38.01	16.96	18	15691	5897	110567693
Hyperkalaemia	37.04	16.96	68	15641	135728	110437862
Fall	35.87	16.96	175	15534	603307	109970283
Intentional overdose	32.00	16.96	63	15646	132438	110441152
Hallucination, visual	29.28	16.96	32	15677	39573	110534017
Completed suicide	29.10	16.96	88	15621	242293	110331297
Febrile neutropenia	29.06	16.96	5	15704	316762	110256828
Treatment failure	28.70	16.96	3	15706	277231	110296359
Presyncope	28.58	16.96	35	15674	48852	110524738
Product residue present	28.45	16.96	13	15696	3928	110569662
Atrial fibrillation	28.16	16.96	84	15625	229558	110344032
Loss of consciousness	27.16	16.96	75	15634	196231	110377359
Urinary straining	27.14	16.96	5	15704	52	110573538
Serum serotonin increased	27.08	16.96	7	15702	375	110573215
Rheumatoid arthritis	26.90	16.96	5	15704	299608	110273982
Heart valve stenosis	26.61	16.96	6	15703	179	110573411
Musculoskeletal stiffness	26.60	16.96	4	15705	279818	110293772
Circumoral swelling	25.90	16.96	5	15704	68	110573522
Labelled drug-drug interaction medication error	25.81	16.96	26	15683	29276	110544314
Wrong technique in product usage process	25.42	16.96	45	15664	87303	110486287
Ventricular tachycardia	24.81	16.96	33	15676	49976	110523614
Aortic bruit	24.36	16.96	6	15703	264	110573326
Nasopharyngitis	24.09	16.96	13	15696	394348	110179242
Circulatory collapse	23.88	16.96	30	15679	42963	110530627
Coronary artery occlusion	23.87	16.96	19	15690	15753	110557837
Torsade de pointes	23.57	16.96	22	15687	22578	110551012
Myopathy	23.56	16.96	23	15686	24937	110548653
Melaena	23.42	16.96	38	15671	68719	110504871
Blood sodium decreased	23.32	16.96	28	15681	38291	110535299
Hallucination	23.01	16.96	47	15662	101385	110472205
Bundle branch block left	22.72	16.96	17	15692	12871	110560719
Cardiac pacemaker insertion	22.69	16.96	13	15696	6288	110567302
Cardiac failure	22.40	16.96	68	15641	187558	110386032
Respiratory tract haemorrhage	22.33	16.96	9	15700	2005	110571585
Myopathy toxic	22.19	16.96	8	15701	1317	110572273
Hepatic enzyme increased	22.02	16.96	9	15700	320883	110252707
Haematemesis	21.97	16.96	34	15675	59074	110514516
Asthenia	21.90	16.96	170	15539	688829	109884761
Chest discomfort	21.69	16.96	64	15645	173784	110399806
Coronary angioplasty	21.68	16.96	6	15703	417	110573173
Brugada syndrome	20.78	16.96	8	15701	1580	110572010
Pyrexia	20.27	16.96	63	15646	898202	109675388
Myocardial necrosis	20.07	16.96	6	15703	549	110573041
Therapeutic product effect decreased	20.05	16.96	5	15704	244311	110329279
Hyponatraemia	19.84	16.96	72	15637	217581	110356009
Anaemia	19.66	16.96	139	15570	546947	110026643
Alopecia	19.54	16.96	14	15695	364739	110208851
Hypotonic urinary bladder	19.47	16.96	4	15705	76	110573514
Gravitational oedema	19.39	16.96	8	15701	1890	110571700
Cardiac disorder	19.30	16.96	37	15672	76243	110497347
Dysarthria	19.11	16.96	39	15670	84082	110489508
Hyperhidrosis	18.83	16.96	64	15645	187234	110386356
Keratolysis exfoliativa acquired	18.56	16.96	3	15706	13	110573577
Vascular graft	18.52	16.96	8	15701	2117	110571473
Ventricular enlargement	18.50	16.96	6	15703	718	110572872
Product prescribing error	18.34	16.96	29	15680	51302	110522288
Vertigo	18.24	16.96	39	15670	86831	110486759
Confusional state	17.96	16.96	121	15588	468559	110105031
Joint swelling	17.85	16.96	22	15687	442823	110130767
Nodal rhythm	17.75	16.96	9	15700	3414	110570176
Dysuria	17.48	16.96	31	15678	60200	110513390

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C01EB18	CARDIOVASCULAR SYSTEM CARDIAC THERAPY OTHER CARDIAC PREPARATIONS Other cardiac preparations
FDA EPC	N0000175427	Anti-anginal
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D026941	Sodium Channel Blockers
MeSH PA	D049990	Membrane Transport Modulators
FDA MoA	N0000182137	Cytochrome P450 2D6 Inhibitors
FDA MoA	N0000185503	P-Glycoprotein Inhibitors
FDA MoA	N0000187061	Organic Cation Transporter 2 Inhibitors
FDA MoA	N0000190114	Cytochrome P450 3A Inhibitors
CHEBI has role	CHEBI:35526	hypoglycemic agent
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:35674	antihypertensive agent
CHEBI has role	CHEBI:38070	anti-arrhythmia drug
CHEBI has role	CHEBI:38633	sodium channel blocker
CHEBI has role	CHEBI:53784	antispasmodic drug
CHEBI has role	CHEBI:231911	renoprotective agent

Related Drugs by ATC class:

C01EB Other cardiac preparations 15 drugs

acadesine acoramidis adenosine camphor creatinolfosfate ibuprofen indomethacin ivabradine mavacamten meldonium phosphocreatine regadenoson show all 15 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Angina pectoris	indication	194828000
Cirrhosis of liver	contraindication	19943007	DOID:5082
Torsades de pointes	contraindication	31722008
Kidney disease	contraindication	90708001	DOID:557
Prolonged QT interval	contraindication	111975006
Congenital long QT syndrome	contraindication	442917000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.4	acidic
pKa2	6.91	Basic
pKa3	2.91	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium channel protein type 5 subunit alpha	Ion channel	Q14524	SCN5A_HUMAN	BLOCKER	IC50	5.17	CHEMBL	CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	4.92	WOMBAT-PK
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN				WOMBAT-PK
Voltage-gated sodium channel Nav1.5 cardiac isoform	Ion channel		Q5YLN7_CANLF		IC50	5.16	CHEMBL

External reference:

ID	Source
4025078	VUID
N0000175343	NUI
D05700	KEGG_DRUG
95635-56-6	SECONDARY_CAS_RN
4025078	VANDF
C0073633	UMLSCUI
CHEBI:87681	CHEBI
CHEMBL1404	ChEMBL_ID
CHEMBL1526084	ChEMBL_ID
D000069458	MESH_DESCRIPTOR_UI
DB00243	DRUGBANK_ID
56959	PUBCHEM_CID
7291	IUPHAR_LIGAND_ID
5946	INN_ID
A6IEZ5M406	UNII
356778	RXNORM
20936	MMSL
309260	MMSL
75657	MMSL
d05719	MMSL
011195	NDDF
420365007	SNOMEDCT_US
420624001	SNOMEDCT_US
A6IEZ5M406	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Ranolazine	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8569	TABLET, FILM COATED, EXTENDED RELEASE	500 mg	ORAL	ANDA	27 sections
Ranolazine	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8611	TABLET, EXTENDED RELEASE	500 mg	ORAL	ANDA	25 sections
Ranolazine	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7506	TABLET, FILM COATED, EXTENDED RELEASE	500 mg	ORAL	ANDA	25 sections
Ranolazine	HUMAN PRESCRIPTION DRUG LABEL	1	13668-759	TABLET, FILM COATED, EXTENDED RELEASE	500 mg	ORAL	ANDA	23 sections
Ranolazine	HUMAN PRESCRIPTION DRUG LABEL	1	13668-760	TABLET, FILM COATED, EXTENDED RELEASE	1000 mg	ORAL	ANDA	23 sections
Ranolazine	Human Prescription Drug Label	1	27241-125	TABLET, EXTENDED RELEASE	500 mg	ORAL	ANDA	27 sections
Ranolazine	Human Prescription Drug Label	1	27241-126	TABLET, EXTENDED RELEASE	1000 mg	ORAL	ANDA	27 sections
Ranolazine	HUMAN PRESCRIPTION DRUG LABEL	1	29300-296	TABLET, FILM COATED, EXTENDED RELEASE	500 mg	ORAL	ANDA	25 sections
Ranolazine	HUMAN PRESCRIPTION DRUG LABEL	1	29300-297	TABLET, FILM COATED, EXTENDED RELEASE	1000 mg	ORAL	ANDA	25 sections
Ranolazine	HUMAN PRESCRIPTION DRUG LABEL	1	31722-668	TABLET, FILM COATED, EXTENDED RELEASE	500 mg	ORAL	ANDA	29 sections
Ranolazine	HUMAN PRESCRIPTION DRUG LABEL	1	31722-669	TABLET, FILM COATED, EXTENDED RELEASE	1000 mg	ORAL	ANDA	29 sections
Ranolazine	HUMAN PRESCRIPTION DRUG LABEL	1	42291-773	TABLET, FILM COATED, EXTENDED RELEASE	500 mg	ORAL	ANDA	22 sections
Ranolazine	HUMAN PRESCRIPTION DRUG LABEL	1	42291-774	TABLET, FILM COATED, EXTENDED RELEASE	1000 mg	ORAL	ANDA	22 sections
Ranolazine	HUMAN PRESCRIPTION DRUG LABEL	1	42571-324	TABLET, EXTENDED RELEASE	500 mg	ORAL	ANDA	26 sections
Ranolazine	HUMAN PRESCRIPTION DRUG LABEL	1	42571-325	TABLET, EXTENDED RELEASE	1000 mg	ORAL	ANDA	26 sections
ASPRUZYO SPRINKLE	HUMAN PRESCRIPTION DRUG LABEL	1	47335-624	GRANULE	500 mg	ORAL	NDA	26 sections
ASPRUZYO SPRINKLE	HUMAN PRESCRIPTION DRUG LABEL	1	47335-625	GRANULE	1000 mg	ORAL	NDA	26 sections
RANOLAZINE	HUMAN PRESCRIPTION DRUG LABEL	1	50228-423	TABLET, FILM COATED, EXTENDED RELEASE	500 mg	ORAL	ANDA	27 sections
RANOLAZINE	HUMAN PRESCRIPTION DRUG LABEL	1	50228-424	TABLET, FILM COATED, EXTENDED RELEASE	1000 mg	ORAL	ANDA	27 sections
Ranolazine	HUMAN PRESCRIPTION DRUG LABEL	1	50268-722	TABLET, FILM COATED, EXTENDED RELEASE	500 mg	ORAL	ANDA	25 sections
Ranolazine	HUMAN PRESCRIPTION DRUG LABEL	1	50268-723	TABLET, FILM COATED, EXTENDED RELEASE	1000 mg	ORAL	ANDA	25 sections
Ranolazine	Human Prescription Drug Label	1	59651-009	TABLET, FILM COATED, EXTENDED RELEASE	500 mg	ORAL	ANDA	27 sections
Ranolazine	Human Prescription Drug Label	1	59651-010	TABLET, FILM COATED, EXTENDED RELEASE	1000 mg	ORAL	ANDA	27 sections
Ranolazine	HUMAN PRESCRIPTION DRUG LABEL	1	60687-549	TABLET, EXTENDED RELEASE	500 mg	ORAL	ANDA	27 sections
Ranexa	HUMAN PRESCRIPTION DRUG LABEL	1	61958-1001	TABLET, FILM COATED, EXTENDED RELEASE	500 mg	ORAL	NDA	29 sections
Ranexa	HUMAN PRESCRIPTION DRUG LABEL	1	61958-1002	TABLET, FILM COATED, EXTENDED RELEASE	1000 mg	ORAL	NDA	29 sections
Ranolazine	HUMAN PRESCRIPTION DRUG LABEL	1	63304-017	TABLET, EXTENDED RELEASE	500 mg	ORAL	ANDA	27 sections
Ranolazine	HUMAN PRESCRIPTION DRUG LABEL	1	63304-018	TABLET, EXTENDED RELEASE	1000 mg	ORAL	ANDA	27 sections
Ranolazine	HUMAN PRESCRIPTION DRUG LABEL	1	63629-4874	TABLET, EXTENDED RELEASE	500 mg	ORAL	ANDA	25 sections
Ranolazine	Human Prescription Drug Label	1	67877-525	TABLET, FILM COATED, EXTENDED RELEASE	500 mg	ORAL	ANDA	25 sections

Ask DrugCentral

Try a sample question

ranolazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: